Receptor activity-modifying proteins (RAMP1-3) determine the selectivity of the class B G protein-coupled calcitonin receptor (CTR) and the CTR-like receptor (CLR) for calcitonin (CT), amylin (Amy), calcitonin gene-related peptide (CGRP), and adrenomedullin (AM) peptides. RAMP1/2 alter CLR selectivity for CGRP/AM in part by RAMP1 Trp-84 or RAMP2 Glu-101 contacting the distinct CGRP/AM C-terminal residues. It is unclear whether RAMPs use a similar mechanism to modulate CTR affinity for CT and Amy, analogs of which are therapeutics for bone disorders and diabetes, respectively. Here, we reproduced the peptide selectivity of intact CTR, AMY 1 (CTR⅐ RAMP1), and AMY 2 (CTR⅐RAMP2) receptors using purified CTR extracellular domain (ECD) and tethered RAMP1-and RAMP2-CTR ECD fusion proteins and antagonist peptides. All three proteins bound salmon calcitonin (sCT). Tethering RAMPs to CTR enhanced binding of rAmy, CGRP, and the AMY antagonist AC413. Peptide alanine-scanning mutagenesis and modeling of receptor-bound sCT and AC413 supported a shared non-helical CGRP-like conformation for their TN(T/ V)G motif prior to the C terminus. After this motif, the peptides diverged; the sCT C-terminal Pro was crucial for receptor binding, whereas the AC413/rAmy C-terminal Tyr had little or no influence on binding. Accordingly, mutant RAMP1 W84A-and RAMP2 E101A-CTR ECD retained AC413/rAmy binding. ECD binding and cell-based signaling assays with antagonist sCT/ AC413/rAmy variants with C-terminal residue swaps indicated that the C-terminal sCT/rAmy residue identity affects affinity more than selectivity. rAmy(8 -37) Y37P exhibited enhanced antagonism of AMY 1 while retaining selectivity. These results reveal unexpected differences in how RAMPs determine CTR and CLR peptide selectivity and support the hypothesis that RAMPs allosterically modulate CTR peptide affinity.Receptor activity-modifying proteins are single-pass transmembrane proteins (RAMP1-3 in humans) that form heteromeric complexes with several G protein-coupled receptors (GPCRs) 2 and thereby regulate their cell-surface expression and pharmacology (1, 2). RAMPs are best characterized for their effects on two class B GPCRs, the calcitonin receptor (CTR) and CTR-like receptor (CLR) (3). CTR/CLR and their complexes with RAMPs give rise to at least seven pharmacologically distinct receptors (not including splice variants) in humans that exhibit unique selectivity profiles for six related calcitonin (CT) family peptide agonists as follows: CT, amylin (Amy), calcitonin gene-related peptides ␣ and  (␣CGRP and CGRP), adrenomedullin (AM), and adrenomedullin2/intermedin (AM2) (2-4). CLR⅐RAMP1 is the CGRP receptor at which CGRP has greater potency than AM. CLR⅐RAMP2 and CLR⅐RAMP3 are the AM 1 and AM 2 receptors, respectively, at which AM is more potent than CGRP (1). AM2 activates the CGRP and AM receptors, but is most potent at AM 2 (5). CTR alone is the CT receptor at which CT is more potent than Amy. CTR complexes with RAMP1, -2, or -3 form distinct AMY 1 , AMY 2 , and AMY 3 rec...